SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-19-017950
Filing Date
2019-11-19
Accepted
2019-11-19 15:20:10
Documents
60
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 779531
2 ex31-1.htm EX-31.1 38268
3 ex32-1.htm EX-32.1 10244
  Complete submission text file 0001493152-19-017950.txt   3503447

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE FILE imun-20190930.xml EX-101.INS 493274
5 XBRL SCHEMA FILE imun-20190930.xsd EX-101.SCH 49541
6 XBRL CALCULATION FILE imun-20190930_cal.xml EX-101.CAL 49476
7 XBRL DEFINITION FILE imun-20190930_def.xml EX-101.DEF 167008
8 XBRL LABEL FILE imun-20190930_lab.xml EX-101.LAB 290527
9 XBRL PRESENTATION FILE imun-20190930_pre.xml EX-101.PRE 239269
Mailing Address 37 NORTH ORANGE AVENUE SUITE 607 ORLANDO FL 32801
Business Address 37 NORTH ORANGE AVENUE SUITE 607 ORLANDO FL 32801 (888) 613-8802
Immune Therapeutics, Inc. (Filer) CIK: 0001559356 (see all company filings)

IRS No.: 593226705 | State of Incorp.: FL | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-54933 | Film No.: 191230893
SIC: 2834 Pharmaceutical Preparations